A Randomised Phase II Study of NivolUmab and TeMozolomide vs Temozolomide Alone in Newly Diagnosed Elderly Patients With Glioblastoma (NUTMEG)
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms NUTMEG
- 13 Jun 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 13 Jun 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Jul 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.